PUFA Phospholipid Microbubbles for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering omega-3 polyunsaturated fatty acids (PUFAs) are limited by slow and variable bioavailability, making them unsuitable for acute medical conditions due to the need for prolonged infusion and unpredictable blood levels, and they are not effectively targeted to specific areas of disease or injury.
Innovation Solution
Phospholipid microbubbles comprising a shell of PUFA-containing phospholipids with a core of inert gas, customized with specific polar head groups and non-polar fatty acid tails, are used for targeted delivery to areas of disease or injury, enhanced by focused ultrasound for rapid release and monitored by MRI.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral supplementation of omega-3 PUFA is used, then patients can take the medication easily, but it requires weeks to months to attain adequate blood levels and has delayed onset of action
Solution Approach 1:
The patent changes the physical and chemical parameters of omega-3 PUFA by incorporating it into phospholipid microbubbles with specific shell compositions and core structures. This formulation transformation enables the substance to be administered intravenously and achieve rapid therapeutic effects within seconds to minutes, resolving the contradiction between ease of administration and time to effect.
Solution Approach 2:
The phospholipid microbubble acts as an intermediary carrier system that facilitates the rapid delivery of omega-3 PUFA to target tissues. The microbubble structure with its specific shell and core composition serves as a mediator between the administered drug and the target site, enabling rapid onset while maintaining ease of intravenous administration.
2Speed
If intravenous infusion of omega-3 PUFA is used to achieve rapid onset of action, then therapeutic effects can be achieved quickly, but the blood levels are highly variable and require prolonged infusion of excess 90 minutes
Solution Approach 1:
The patent replaces the mechanical system of prolonged intravenous infusion with a targeted delivery system using phospholipid microbubbles. The microbubbles are designed to naturally target and accumulate at the site of injury or disease, eliminating the need for prolonged infusion times while maintaining rapid onset of action. The targeting is achieved through the specific phospholipid composition rather than mechanical infusion control.
Solution Approach 2:
The phospholipid microbubble formulation exhibits self-targeting capabilities, automatically accumulating at sites of injury or disease without requiring external control or prolonged administration. The microbubbles self-direct to the target tissue through their specific phospholipid composition, reducing infusion time and eliminating the need for extended administration protocols.
3Reliability
If omega-3 PUFA are administered to treat acute conditions like myocardial infarction, then rapid therapeutic effect is needed, but current methods have unpredictable bioavailability and cannot be reliably used in emergent situations
Solution Approach 1:
The patent applies local quality by designing phospholipid microbubbles with specific shell compositions and core structures that enable selective accumulation at the site of injury or disease. This localized targeting ensures reliable and predictable therapeutic effects at the target site while maintaining rapid delivery speed, making the treatment suitable for acute conditions like myocardial infarction.
Solution Approach 2:
The phospholipid microbubble formulation is prepared in advance with optimized composition and structure that enables immediate targeting and rapid therapeutic effect upon intravenous administration. The preliminary formulation work ensures that when administered in acute situations, the microbubbles reliably and rapidly deliver omega-3 PUFA to the target site without requiring adjustment or prolonged infusion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for rapid, efficient, and targeted delivery of PUFAs to specific areas, achieving therapeutic effects within seconds to minutes, reducing systemic side effects and enabling treatment of acute conditions like myocardial infarction and arrhythmic complications.
Implementation Method 1
customized with specific polar head groups and non-polar fatty acid tails, are used for targeted delivery to areas of disease or injury, enhanced by focused ultrasound for rapid release
Implementation Method 2
enhanced by focused ultrasound for rapid release and monitored by MRI
Data Source
AI summary
A phospholipid microbubble comprising a shell which comprises a plurality of polyunsaturated fatty acid (“PUFA”)-containing phospholipids, and a core of inert gas surrounded by the shell comprising the plurality of PUFA-containing phospholipids. The present invention also provides methods of delivering a prophylactically or therapeutically effective amount of PUFA to an area of disease or injury in a subject. The present invention also provides methods of preventing or treating a disease in a subject using a prophylactically or therapeutically effective amount of the aforementioned phospholipid microbubbles.